GU Cancers 2019 | Impact of specific mutations on PARP inhibition in prostate cancer

Name: Impact of specific mutations on PARP inhibition in prostate cancer
Uploaded: 2019-03-06T11:07:04Z
Duration: 3 min 13 s
Description: Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He dicusses a recent publication by his group on the impact of certain genes mutations on PARP inhibition in prostate cancer, including ATM, CDK12 and BRCA1/2.

Emmanuel Antonarakis • 6 Mar 2019

GU Cancers 2019

Genitourinary Cancer Prostate Cancer Rucaparib

Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He dicusses a recent publication by his group on the impact of certain genes mutations on PARP inhibition in prostate cancer, including ATM, CDK12 and BRCA1/2.